Investor FAQs
Pear Therapeutics, Inc. (“Pear Therapeutics”) is headquartered in Boston, MA. Our mailing address is 200 State Street, 13th floor, Boston, MA 02109. Pear Therapeutics (US), Inc. is the operating company of Pear Therapeutics, Inc. Pear has offices in Boston, MA, Raleigh, NC and San Francisco, CA.
The website address is www.peartherapeutics.com.
Pear Therapeutics was founded in 2013 and is incorporated in the state of Delaware.
Pear Therapeutics common stock trades on the Nasdaq under the ticker “PEAR”.
The Company’s (i) common stock CUSIP number is 704723 105 and (ii) warrant CUSIP number is 704723 113.
Shares of Pear Therapeutics can be purchased through the broker of your choice.
Continental Stock Transfer & Trust Company
Pear has more than 250 employees that make up a dedicated, cross-functional team operating at the intersection of biology and software technology.
Pear Therapeutics’ fiscal year ends December 31.
Pear Therapeutics’ independent auditing firm is Deloitte & Touche LLP with offices in Boston, MA.
To review the corporate governance policies of Pear Holdings, please visit the Corporate Governance section of the website.
8-K, quarterly and annual reports and other investor materials are available under the SEC Filings section of the website. Additionally, all SEC filings can also be viewed directly on the SEC website.
Pear Therapeutics will issue a press release that includes the date of our quarterly earnings call. These releases, which will be issued approximately 2 weeks prior to the corresponding calls, will be posted on the News and Press Releases section of our website, including the details for accessing the conference call and/or webcast to discuss the results.
If you wish to contact our investor relations team, please send an email to IR@peartherapeutics.com.
To automatically receive financial information by email, please visit the Email Alerts section of this website.
Please visit the Events section of the Investor Website.